Type 2 Diabetes: A Complete Guide to Prevention, Diagnosis, and Daily Management
Type 2 diabetes is the most widespread metabolic disease globally: in Italy, there are 3.7 million diagnosed diabetics, and it is estimated that another 1.5 million are not yet aware they have it. This guide explains everything you need to know, from causes to diagnosis, therapeutic goals, and daily monitoring tools.
What is Type 2 Diabetes
Type 2 diabetes mellitus is a chronic metabolic disease characterized by persistent hyperglycemia — chronically elevated blood glucose levels. It develops through two mechanisms that often coexist:
- Insulin resistance: Muscle, fat, and liver cells do not respond adequately to insulin, reducing glucose uptake.
- Progressive decline in insulin secretion: The pancreas cannot produce enough insulin to compensate for the resistance.
The result is a chronic increase in blood sugar which, over time, damages blood vessels, nerves, kidneys, retina, and heart.
Epidemiological Data in Italy
- 3.7 million Italians have diagnosed diabetes (ISS 2025)
- 90–95% of cases are type 2 diabetes
- Approximately 1.5 million are undiagnosed diabetics
- Over 4 million have pre-diabetes
- The direct cost of diabetes to the National Health Service is €9.2 billion/year (Osservasalute 2024)
- Diabetes is responsible for 40% of non-traumatic lower limb amputations and 30% of end-stage renal failure cases
Risk Factors
Non-modifiable
- Age > 45 years (risk doubles every decade after 40)
- Family history (parent or sibling with type 2 diabetes: 2–4 times higher risk)
- Previous gestational diabetes or child born > 4.5 kg
- Ethnicity (Asian, African, Latin American populations have a higher risk)
Modifiable (actionable)
- Overweight/obesity: The main modifiable risk factor; BMI > 25 triples the risk
- Visceral fat: Regardless of weight, abdominal fat distribution is an independent risk factor
- Sedentary lifestyle: Increases risk by 30–50%
- High GI diet: High consumption of sugary drinks, refined carbohydrates
- Pre-diabetes: Fasting blood glucose 100–125 mg/dL or OGTT 140–199 mg/dL
- Arterial hypertension: Concurrent presence increases risk by 40%
- Dyslipidemia: High triglycerides and low HDL (metabolic syndrome)
- Sleep apnea: Associated with insulin resistance
Diagnosis: Official Criteria
The diagnosis of diabetes mellitus requires one of the following criteria, confirmed by two separate blood tests (unless classic symptoms + random blood glucose ≥ 200 mg/dL):
| Test | Diabetes threshold | Pre-diabetes threshold |
|---|---|---|
| Fasting blood glucose (≥8h) | ≥ 126 mg/dL | 100–125 mg/dL |
| OGTT 2h (75 g glucose) | ≥ 200 mg/dL | 140–199 mg/dL |
| HbA1c | ≥ 6.5% | 5.7–6.4% |
| Random blood glucose | ≥ 200 mg/dL + symptoms | — |
Source: ADA Standards of Care 2025; Italian AMD-SID Standards 2024.
Symptoms of Type 2 Diabetes
Unlike type 1, type 2 diabetes develops slowly and can be asymptomatic for years. When symptoms appear:
- Polyuria: Frequent and abundant urination
- Polydipsia: Intense and persistent thirst
- Chronic fatigue and decreased energy
- Blurred vision (excess glucose alters the shape of the lens)
- Slow healing of wounds
- Recurrent infections (urinary, skin, candidiasis)
- Tingling or numbness in the feet (early peripheral neuropathy)
- Unintentional weight loss (less common than in type 1)
Glycemic Targets for Type 2 Diabetes Under Treatment
| Parameter | Standard target | Healthy elderly target | Frail elderly target |
|---|---|---|---|
| HbA1c | < 7.0% | < 7.5% | < 8.0–8.5% |
| Fasting blood glucose | 80–130 mg/dL | 90–150 mg/dL | 100–180 mg/dL |
| 2h postprandial blood glucose | < 180 mg/dL | < 200 mg/dL | < 220 mg/dL |
| Blood pressure | < 130/80 mmHg | < 140/90 mmHg | < 150/90 mmHg |
| LDL-cholesterol | < 70 mg/dL | < 70–100 mg/dL | Individualized |
Source: AMD-SID Italian Standards 2024; ESC Guidelines on Cardiovascular Disease Prevention 2023.
Pharmacological Therapy for Type 2 Diabetes
Therapy is personalized based on the patient's profile, cardiovascular risk, renal function, and individual preferences:
First-line
- Metformin: First-choice drug, reduces HbA1c by 1–2%, protects cardiovascularly, weight-neutral, economical. To be taken with meals to reduce gastrointestinal side effects.
Cardiovascularly protective drugs (preferred in high-CV-risk patients)
- SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin): Reduce HbA1c, weight (-2–4 kg), blood pressure, and have demonstrated cardio and renoprotective effects
- GLP-1 agonists (semaglutide, dulaglutide, liraglutide): Significantly reduce HbA1c and weight (-4–10 kg), reduce cardiovascular events, injectable (weekly or daily)
Second-line drugs
- DPP-4 inhibitors (sitagliptin, vildagliptin): Weight-neutral, well-tolerated, moderate efficacy
- Sulfonylureas: Effective but risk of hypoglycemia and weight gain
- Basal insulin: When targets are not achievable with oral medications
Lifestyle: The Most Powerful Intervention
Lifestyle modifications reduce HbA1c by 1–2% — as much as a second-line drug — and simultaneously address all cardiovascular risk factors:
- Weight loss: Every 1 kg lost improves fasting blood glucose by 2–4 mg/dL. A 10–15% weight loss (with bariatric surgery or GLP-1) leads to diabetes remission in 30–60% of cases
- Physical activity: 150 min/week of aerobic + 2 resistance sessions reduce HbA1c by 0.5–1%
- Low GI diet: Reduces postprandial glycemic excursions
- Sodium reduction: Controls blood pressure (frequently elevated in diabetics)
Home Monitoring with a Glucometer
Self-monitoring of blood glucose (SMBG) is one of the most effective tools for managing type 2 diabetes. It allows you to:
- Verify the effectiveness of pharmacological therapy
- Identify meals that cause blood glucose spikes
- Early recognition of hypoglycemia
- Provide objective data to the diabetologist to adjust therapy
Clinical studies show that type 2 diabetes patients who perform regular SMBG and share data with their diabetologist have HbA1c on average 0.5% lower and a reduced risk of complications (BMJ Open Diabetes Research & Care 2023).
The VitaeChek G1 Pro is designed to make this monitoring simple: automatic Bluetooth, app with trend graph, shareable PDF report, and voice announcement of results in Italian.
Complications of Type 2 Diabetes: How to Prevent Them
Optimal glycemic control significantly reduces the risk of all chronic complications:
- Diabetic nephropathy: Risk reduced by 35–40% for every 1% reduction in HbA1c
- Diabetic retinopathy: Risk reduced by 25–35%
- Peripheral neuropathy: Risk reduced by 25%
- Myocardial infarction: Risk reduced by 14–16%
- Stroke: Risk reduced by 12%
- Amputations: Risk reduced by 40–50% with glycemic control + foot care
Frequently Asked Questions
Can type 2 diabetes be cured?
In some cases, yes — this is referred to as "remission." With significant weight loss (≥10–15%), 30–60% of type 2 diabetics achieve normal blood glucose levels without medication for at least 1 year. Remission is more likely at the beginning of the disease and with rapid, sustained weight loss.
Can I stop medication if my blood glucose is at target?
Only under medical supervision. If lifestyle changes stably bring HbA1c below 6.5% for 3–6 months, your doctor may consider reducing therapy. Never stop autonomously.
Does type 2 diabetes lead to type 1?
No — they are two distinct diseases with completely different mechanisms. Type 1 is autoimmune (the immune system destroys pancreatic beta cells); type 2 is metabolic (insulin resistance + relative insulin deficiency). One cannot "become" type 1 from type 2.